Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. (Record no. 29400435)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02258 a2200637 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518024146.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201912s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1532-1827 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1038/s41416-019-0389-6 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Serrano, César |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20191216 |
| 245 00 - TITLE STATEMENT | |
| Title | Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | British journal of cancer |
| Date of publication, distribution, etc. | 03 2019 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 612-620 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Animals |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | CHO Cells |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Clinical Trials, Phase II as Topic |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cricetulus |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Resistance, Neoplasm |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gastrointestinal Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gastrointestinal Stromal Tumors |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Imatinib Mesylate |
| General subdivision | pharmacology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mice |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mice, Nude |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mutation |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phenylurea Compounds |
| General subdivision | pharmacology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Protein Kinase Inhibitors |
| General subdivision | pharmacology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Proto-Oncogene Proteins c-kit |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pyridines |
| General subdivision | pharmacology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Sunitinib |
| General subdivision | pharmacology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Xenograft Model Antitumor Assays |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mariño-Enríquez, Adrián |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tao, Derrick L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ketzer, Julia |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Eilers, Grant |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zhu, Meijun |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yu, Channing |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mannan, Aristotle M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rubin, Brian P |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Demetri, George D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Raut, Chandrajit P |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Presnell, Ajia |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | McKinley, Arin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Heinrich, Michael C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Czaplinski, Jeffrey T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sicinska, Ewa |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bauer, Sebastian |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | George, Suzanne |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fletcher, Jonathan A |
| 773 0# - HOST ITEM ENTRY | |
| Title | British journal of cancer |
| Related parts | vol. 120 |
| -- | no. 6 |
| -- | p. 612-620 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1038/s41416-019-0389-6">https://doi.org/10.1038/s41416-019-0389-6</a> |
| Public note | Available from publisher's website |
No items available.